Drug Trial Radar · NCT00360308
Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
Last checked: Nov 19, 2026Latest source record: Jul 11, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
723
Actual
Start
Nov 2006
Primary completion
Apr 2008
Study completion Apr 2008
Sponsor
- Lead sponsor
- Eisai LimitedEisai
- Sponsor type
- Industry
- First posted
- Aug 4, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Randomised, double-blind, double dummy, parallel group design. Following the screening period patients will be randomised at the baseline visit, in a 1:1:1 manner, to one of three treatment arms; 4 mg E2007, 200 mg entacapone (with each dose of levodopa) or placebo. The first 4 weeks of the double blind phase will be used to titrate patients on the E2007 arm from 2 mg up to the maintenance dose of 4 mg. Patients randomised to entacapone or placebo will have dummy up titrations to maintain the blind. Following this titration phase, patients will remain on the maintenance dose for a further 14 weeks. Patients will have visits at 2, 4, 6, 10, 14 and 18 weeks after baseline. A follow up visit will be performed at Week 22. A home diary will be completed in which patients rate themselves as either: 1. "OFF" 2. "ON" without dyskinesias 3. "ON" with non-troublesome dyskinesias 4. "ON" with troublesome dyskinesias 5. Asleep These entries will be completed every 30 minutes during the waking day and will be completed for three consecutive days immediately prior to visits at Baseline, Weeks 6, 10, 18 and 22. At Baseline (Day 0), week 10 and 18 the Unified Parkinson's Disease Rating Scale (UPDRS - Parts I, II , III and IV) will be performed. At the end of the treatment period (Week 18), patients will undergo final efficacy and safety assessments and will stop taking the study medication they were receiving. They will be seen 4 weeks later for a follow up visit.
Conditions
- Parkinson's Disease
Interventions
PlaceboDrug
E2007Drug
E2007Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Total Daily OFF Time (Hours) to Week 18 (Including LOCF Data)Time frame: Baseline and Week 18
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pavillon Riser- Hopital Purpan
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.